130 related articles for article (PubMed ID: 33754503)
1. Relationships between circulating galectin-3, extracellular matrix fibrosis and outcomes in dilated cardiomyopathy.
Rubiś P; Holcman K; Dziewięcka E; Wiśniowska-Śmiałek S; Karabinowska A; Szymonowicz M; Khachatryan L; Wypasek E; Garlitski A; Gackowski A; Podolec P
Adv Clin Exp Med; 2021 Mar; 30(3):245-253. PubMed ID: 33754503
[TBL] [Abstract][Full Text] [Related]
2. Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy.
Rubiś P; Wiśniowska-Śmialek S; Wypasek E; Biernacka-Fijalkowska B; Rudnicka-Sosin L; Dziewiecka E; Faltyn P; Khachatryan L; Karabinowska A; Kozanecki A; Tomkiewicz-Pająk L; Podolec P
Inflamm Res; 2016 Dec; 65(12):941-949. PubMed ID: 27516211
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of fibrosis-related markers in dilated cardiomyopathy: A link between osteopontin and cardiovascular events.
Rubiś P; Wiśniowska-Śmiałek S; Dziewięcka E; Rudnicka-Sosin L; Kozanecki A; Podolec P
Adv Med Sci; 2018 Mar; 63(1):160-166. PubMed ID: 29120858
[TBL] [Abstract][Full Text] [Related]
4. 12-month patterns of serum markers of collagen synthesis, transforming growth factor and connective tissue growth factor are similar in new-onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis.
Rubiś P; Wiśniowska-Smiałek S; Wypasek E; Rudnicka-Sosin L; Hlawaty M; Leśniak-Sobelga A; Kostkiewicz M; Podolec P
Cytokine; 2017 Aug; 96():217-227. PubMed ID: 28460256
[TBL] [Abstract][Full Text] [Related]
5. Left ventricular reverse remodeling is not related to biopsy-detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR.
Rubiś P; Wiśniowska-Śmiałek S; Biernacka-Fijałkowska B; Rudnicka-Sosin L; Wypasek E; Kozanecki A; Dziewięcka E; Faltyn P; Karabinowska A; Khachatryan L; Hlawaty M; Leśniak-Sobelga A; Kostkiewicz M; Płazak W; Podolec P
Heart Vessels; 2017 Jun; 32(6):714-725. PubMed ID: 28004175
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of selected serum markers of fibrosis in patients with dilated cardiomyopathy and different grades of diastolic dysfunction of the left ventricle.
Wiśniowska-Śmiałek S; Dziewięcka E; Holcman K; Wypasek E; Khachatryan L; Karabinowska A; Szymonowicz M; Leśniak-Sobelga A; Hlawaty M; Kostkiewicz M; Podolec P; Rubiś P
Cardiol J; 2020; 27(6):726-734. PubMed ID: 30484268
[TBL] [Abstract][Full Text] [Related]
7. Right ventricular morphology and function is not related with microRNAs and fibrosis markers in dilated cardiomyopathy.
Rubiś P; Totoń-Żurańska J; Wiśniowska-Śmiałek S; Kołton-Wróż M; Wołkow P; Wypasek E; Rudnicka-Sosin L; Pawlak A; Kozanecki K; Tomkiewicz-Pająk L; Podolec P
Cardiol J; 2018; 25(6):722-731. PubMed ID: 28840590
[TBL] [Abstract][Full Text] [Related]
8. The relationship between myocardial fibrosis and myocardial microRNAs in dilated cardiomyopathy: A link between mir-133a and cardiovascular events.
Rubiś P; Totoń-Żurańska J; Wiśniowska-Śmiałek S; Dziewięcka E; Kołton-Wróż M; Wołkow P; Pitera E; Rudnicka-Sosin L; Garlitski AC; Gackowski A; Podolec P
J Cell Mol Med; 2018 Apr; 22(4):2514-2517. PubMed ID: 29377565
[TBL] [Abstract][Full Text] [Related]
9. Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy.
Vergaro G; Del Franco A; Giannoni A; Prontera C; Ripoli A; Barison A; Masci PG; Aquaro GD; Cohen Solal A; Padeletti L; Passino C; Emdin M
Int J Cardiol; 2015 Apr; 184():96-100. PubMed ID: 25697876
[TBL] [Abstract][Full Text] [Related]
10. Galectin-3 deficiency ameliorates fibrosis and remodeling in dilated cardiomyopathy mice with enhanced Mst1 signaling.
Nguyen MN; Ziemann M; Kiriazis H; Su Y; Thomas Z; Lu Q; Donner DG; Zhao WB; Rafehi H; Sadoshima J; McMullen JR; El-Osta A; Du XJ
Am J Physiol Heart Circ Physiol; 2019 Jan; 316(1):H45-H60. PubMed ID: 30387702
[TBL] [Abstract][Full Text] [Related]
11. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.
Lin YH; Lin LY; Wu YW; Chien KL; Lee CM; Hsu RB; Chao CL; Wang SS; Hsein YC; Liao LC; Ho YL; Chen MF
Clin Chim Acta; 2009 Nov; 409(1-2):96-9. PubMed ID: 19747906
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin.
López B; González A; Querejeta R; Zubillaga E; Larman M; Díez J
Eur J Heart Fail; 2015 Apr; 17(4):385-92. PubMed ID: 25684565
[TBL] [Abstract][Full Text] [Related]
13. Astragaloside IV attenuates myocardial fibrosis by inhibiting TGF-β1 signaling in coxsackievirus B3-induced cardiomyopathy.
Chen P; Xie Y; Shen E; Li GG; Yu Y; Zhang CB; Yang Y; Zou Y; Ge J; Chen R; Chen H
Eur J Pharmacol; 2011 May; 658(2-3):168-74. PubMed ID: 21371462
[TBL] [Abstract][Full Text] [Related]
14. Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients.
Hu DJ; Xu J; Du W; Zhang JX; Zhong M; Zhou YN
Int J Cardiovasc Imaging; 2016 Dec; 32(12):1725-1733. PubMed ID: 27566192
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy.
Schwartzkopff B; Fassbach M; Pelzer B; Brehm M; Strauer BE
Eur J Heart Fail; 2002 Aug; 4(4):439-4. PubMed ID: 12167381
[TBL] [Abstract][Full Text] [Related]
16. Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis: Implications for Its Use as a Biomarker.
Besler C; Lang D; Urban D; Rommel KP; von Roeder M; Fengler K; Blazek S; Kandolf R; Klingel K; Thiele H; Linke A; Schuler G; Adams V; Lurz P
Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28288987
[TBL] [Abstract][Full Text] [Related]
17. Relations between circulating and myocardial fibrosis-linked microRNAs with left ventricular reverse remodeling in dilated cardiomyopathy.
Dziewięcka E; Totoń-Żurańska J; Wołkow P; Kołton-Wróż M; Pitera E; Wiśniowska-Śmiałek S; Khachatryan L; Karabinowska A; Szymonowicz M; Podolec P; Rubiś P
Adv Clin Exp Med; 2020 Mar; 29(3):285-293. PubMed ID: 32207584
[TBL] [Abstract][Full Text] [Related]
18. Serum Matrix Metalloproteinases as Quantitative Biomarkers for Myocardial Fibrosis and Sudden Cardiac Death Risk Stratification in Patients With Hypertrophic Cardiomyopathy.
Münch J; Avanesov M; Bannas P; Säring D; Krämer E; Mearini G; Carrier L; Suling A; Lund G; Patten M
J Card Fail; 2016 Oct; 22(10):845-50. PubMed ID: 27018569
[TBL] [Abstract][Full Text] [Related]
19. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
[TBL] [Abstract][Full Text] [Related]
20. Endothelial‑to‑mesenchymal transition in human idiopathic dilated cardiomyopathy.
Xie Y; Liao J; Yu Y; Guo Q; Yang Y; Ge J; Chen H; Chen R
Mol Med Rep; 2018 Jan; 17(1):961-969. PubMed ID: 29115553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
